513 material Form 8-K filings that 427 companies we cover made with the SEC in November 2024, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Protagonist said its Phase 3 ICONIC-LEAD and ICONIC-TOTAL studies of icotrokinra in plaque psoriasis met their primary endpoints. Under a November 13, 2024 amendment to its collaboration with Janssen, the company has earned a $165 million milestone, which it expects to receive in Q1 2025, and the filing states the payment is not refundable. The filing does not provide revenue, profit or guidance figures.
ICONIC-LEAD: 64.7% of patients reached IGA 0/1 at week 16 on icotrokinra vs. 8.3% on placebo; 49.6% reached PASI 90 vs. 4.4% on placebo.
Amendment raised the Phase 3 milestone by $50 million to $165 million and eliminated $35 million and $15 million milestone payments, which accelerates them into the $165 million.
Company expects to receive the $165 million in Q1 2025 and remains eligible for up to $630 million in future milestones plus tiered royalties of 6-10% on worldwide net sales.
ADM reported third quarter 2024 GAAP net earnings attributable to the company of $18 million, or $0.04 per diluted share, compared with $821 million, or $1.52 per share, a year earlier. The results include a $461 million non-cash impairment charge on its Wilmar equity investment, and adjusted EPS was $1.09. ADM also filed restated financial statements for fiscal 2023 and the first two quarters of 2024, which it says did not affect consolidated results, and affirmed its full-year 2024 adjusted EPS range of $4.50 to $5.00.
Revenues were $19.9 billion, down from $21.7 billion in the prior-year quarter.
Total segment operating profit was $1,037 million, down 28% from $1,446 million.
Full-year 2024 adjusted EPS guidance of $4.50 to $5.00 was affirmed, not changed.
Fourth quarter AS&O segment operating profit is expected to be lower than a year earlier; Nutrition is expected to be higher than a year earlier but lower than the third quarter.
AECOM reported fiscal fourth-quarter 2024 revenue of $4.1 billion, up 7% from a year earlier, with diluted EPS of $1.25 as reported and adjusted EPS up 26%. It guided fiscal 2025 adjusted EPS to $5.00 to $5.20 and raised its quarterly dividend 18% to $0.26 and its share repurchase authorization to $1 billion, which affects per-share returns for shareholders.
Q4 fiscal 2024 diluted EPS was $1.25 as reported, versus $0.24 a year earlier; adjusted EPS rose 26%
Full-year fiscal 2024 revenue was $16.1 billion, up 12%, and free cash flow was $708 million
Fiscal 2025 guidance includes adjusted EPS of $5.00 to $5.20 and adjusted EBITDA of $1,170 million to $1,210 million
Quarterly dividend raised to $0.26 from $0.22, payable January 17, 2025, to holders of record on January 2, 2025
CVS Health increased its board from 12 to 16 members on November 17, 2024, appointing Leslie Norwalk, Larry Robbins, Guy Sansone and Doug Shulman, after discussions with activist investor Glenview Capital Management. The company also entered a confidentiality agreement with Glenview that includes customary standstill and non-disparagement terms, and the filing describes compensation changes for two senior executives.
Board expanded from 12 to 16 members; Norwalk, Robbins, Sansone and Shulman appointed November 17, 2024
Company agreed to nominate all four for election at the 2025 annual meeting of stockholders
Glenview standstill restrictions remain in effect until 30 days before the stockholder nomination window for the 2026 annual meeting
Premium-priced stock options with grant date values of $12,000,000 for CEO J. David Joyner and $6,000,000 for Prem S. Shah, granted November 30, 2024
Broadstone Net Lease said its total estimated build-to-suit development commitments are now $246.5 million, to be funded through the second quarter of 2026, down from $418.8 million in its October 30, 2024 release. A prospective tenant for a large build-to-suit project in the pipeline changed its strategy after an unanticipated executive leadership change and chose not to proceed, including with the Company's transaction, which lowers the development growth pipeline shareholders had been counting on.
Total estimated build-to-suit commitments of $246.5 million, down from $418.8 million reported on October 30, 2024.
A prospective tenant shifted strategy after an unanticipated executive leadership change and declined a large build-to-suit transaction in the pipeline.
Of the $246.5 million, $125.4 million is for developments actively under construction and $121.1 million is additional development commitments.
CEO John Moragne, CFO Kevin Fennell and Brent Maedl will participate in Nareit REITworld 2024 in Las Vegas on November 19 and 20, 2024.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.